PBYI Puma Biotechnology Inc

79.75
+1.70  (2%)
Previous Close 78.05
Open 77.65
Price To book 17.23
Market Cap 2.95B
Shares 36,966,000
Volume 2,125,569
Short Ratio 5.91
Av. Daily Volume 1,639,230

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Note this trial is conducted by competitor Roche (RHHBY), NOT by Puma. The data will likely have a significant impact on the share price of Puma (e.g. positive data would likely have a negative impact on Puma and vice versa). Primary endpoint was met March 2, 2017. Late breaker at ASCO - June 5, 2017. Abstract LBA500.
Roche (RHHBY) - Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Phase 2 data due 2Q 2017.
Neratinib
HER2-positive metastatic breast cancer patients with brain metastases
Phase 3 planned
Neratinib plus temsirolimus
Fourth line HER2-positive metastatic breast cancer
Phase 2 biomarker data released December 7, 2016.
PB272 (NSABP FB-7)
Neoadjuvant treatment for patients with HER2-positive breast cancer
Phase 2 preliminary data released December 8, 2016 with further data presented April 2, 2017.
Neratinib SUMMIT
HER2 non-amplified breast cancer that has a HER2 mutation
Phase 2 additional data released December 8 2016 and April 4, 2017. Noted high rates of diarrhea.
Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL
Extended adjuvant treatment of early stage HER2-positive breast cancer
Phase 3 data due 2Q 2017.
Neratinib
Third-line HER2-positive metastatic breast cancer
Phase 2 completed.
Neratinib - NEfERTT trial
HER2-positive breast cancer first line
NDA filing announced July 21, 2016. Announced acceptance of NDA Filing September 20, 2016. PDUFA estimate July 21, 2017. Advisory Committee Meeting May 24, 2017 voted 12-4 in favor of recommending approval.
PB272 ExteNET trial
Extended adjuvant HER2-positive early stage breast cancer

Latest News

  1. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI
  2. Puma Soaring After Neratinib FDA Panel Win, Time to Buy?
  3. Will Puma Biotechnology (PBYI) Continue to Surge Higher?
  4. Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential
  5. INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 - PBYI
  6. Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring
  7. Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session
  8. This Biotech Stock Has Soared 84% This Week On Breast-Cancer Drug News
  9. Why Abercrombie & Fitch, Triumph Group, and Puma Biotechnology Jumped Today
  10. Why Puma Biotechnology Inc Jumped Higher Today
  11. Puma Biotech shares surge 20% after FDA advisory committee votes in favor of approving breast cancer drug
  12. Puma Biotech Gets Favorable FDA Vote On Neratinib
  13. Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib
  14. FDA Panel Votes 12 To 4 to Approve Puma's Breast Cancer Drug
  15. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Puma Biotechnology, Inc. (PBYI) and Lead Plaintiff Deadline: July 7, 2017
  16. Puma Biotechnology FDA Live Blog
  17. The Current State Of The Breast Cancer Treatment Space
  18. Why Puma Biotechnology, Applied Optoelectronics, and Ferroglobe Jumped Today
  19. Puma Biotech Surges To 6-Month High On Likely Cancer Drug Approval
  20. Puma Biotech Shares Are Roaring On An FDA Review. Here's What Could Still Go Wrong